



19 February 2024

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

technegas
cyclomedica

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Cyclopharm Appoints John Wigglesworth as a Non-Executive Director

Cyclopharm Limited (ASX:CYC) is delighted to welcome Mr. John Wigglesworth to its Board as a Non-Executive Director. Mr. Wigglesworth brings with him 37 years of professional experience, including nearly 25 years as a Partner at KPMG. His diverse background as a Chartered Accountant and Company Director, coupled with his extensive industry experience, positions him as a valuable addition to Cyclopharm's Board of Directors.

Mr. Wigglesworth's career highlights include:

- Experienced company director having held several previous Board positions over the past decade including Atlas Arteria Limited (ASX:ALX) and also in public sector health entities.
- While at KPMG John advised and supported many leading Australian and international multi-national companies during periods of international growth.
- Held various KPMG leadership positions including serving as a member of the Audit Leadership Group and National leader of KPMG Audit's Retention & Conversion function, managing proposals, client relationship management, and global management groups/committees.
- Expertise in ASX listing readiness, IPOs, and business transition, working closely with companies navigating the challenges of transitioning to a listed entity.
- Financial reporting and market communications specialist, with a focus on ASX and regulatory reporting along with broader financial reporting matters.
- Strong background in internal control and accounting processes, including applying Lean principles and advising on system design.
- Extensive experience in risk management, including Cyber, and serving as Chairman of the Audit & Risk Committee at both Atlas Arteria Limited and Macquarie University.

With Mr. Wigglesworth's strategic insights and the recent USFDA approval of Technegas in the United States, Cyclopharm Limited anticipates substantial growth. The Board believes that Mr. Wigglesworth's extensive experience will contribute significantly to the company's strategic direction, governance, and overall success.

Comment from Chairman, Mr. David Heaney: *"We are thrilled to have John join our Board. His extensive experience and deep industry knowledge will undoubtedly strengthen our board and serve as a valuable resource for our management. We look forward to benefiting from his strategic insights as we continue to navigate and capitalize on the exciting opportunities ahead."*

Comment from CEO, Mr. James McBrayer: *"The recent USFDA approval of Technegas marks a pivotal moment for Cyclopharm, and John's appointment further enhances our ability to capitalize on this milestone. His expertise aligns with our growth strategy, and we are confident that together with the board and management, we will drive Cyclopharm to new heights."*

[ENDS]

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please refer to our website at www.cyclopharm.com or contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas™ used in functional lung ventilation imaging.

Technegas™

The Technegas™ technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas™, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.